Alzheimer’s disease therapies: Selected advances and future perspectivesFootnote

Peer review under responsibility of Alexandria University Faculty of Medicine.

Footnote

Available online 18 October 2014

References

• M.MedinaJ.AvilaNew perspectives on the role of tau in Alzheimer’s disease. Implications for therapyBiochem Pharmacol201410.1016/j.bcp.2014.01.013
   Web of Science ®Google Scholar
• B.M.ShahM.MisraC.J.ShishooH.PadhNose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterizationDrug Delivery201410.3109/10717544.2013.878857
   Web of Science ®Google Scholar
• H.GharaeiH.ShadlouA brief report on the efficacy of donepezil in pain management in Alzheimer’s diseaseJ Pain Palliat Care Pharmacother201410.3109/15360288.2013.876484
   Google Scholar
• M.M.MielkeP.VemuriW.A.RoccaClinical epidemiology of Alzheimer’s disease: assessing sex and gender differencesClin Epidemiol620143748
   PubMed Web of Science ®Google Scholar
• B.WinbladA.GrafM.E.RiviereN.AndreasenJ.M.RyanActive immunotherapy options for Alzheimer’s diseaseAlzheimer’s Res Ther620147
   PubMed Web of Science ®Google Scholar
• B.UrbanovaA.TomekR.MikulikH.MagerovaD.HorinekJ.HortNeurosonological examination: a non-invasive approach for the detection of cerebrovascular impairment in ADFront Behav Neurosci820144
   PubMed Web of Science ®Google Scholar
• E.LonatiA.BrambillaC.MilaniM.MasseriniP.PalestiniA.BulbarelliPin1, a new player in the fate of HIF-1alpha degradation: an hypothetical mechanism inside vascular damage as Alzheimer’s disease risk factorFront Cell Neurosci820141
   Web of Science ®Google Scholar
• N.XiaL.LiuMetallothioneins and synthetic metal chelators as potential therapeutic agents for removal of aberrant metal ions from metal-abeta speciesMini Rev Med Chem201410.2174/1389557514666140123124841
   Web of Science ®Google Scholar
• T.L.Spires-JonesT.FriedmanR.PitstickMethylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathyNeurosci Lett56220146368
   PubMed Web of Science ®Google Scholar
• J.LuoJ.P.AbrahamsCyclic peptides as inhibitors of amyloid fibrillationChemistry201410.1002/chem.201304253
   Web of Science ®Google Scholar
• R.LiuJ.Z.LiJ.K.SongPinocembrin improves cognition and protects the neurovascular unit in Alzheimer related deficitsNeurobiol Aging201310.1016/j.neurobiolaging.2013.12.031
   Web of Science ®Google Scholar
• A.SclipA.TozziA.AbazaC-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivoCell Death Dis52014e1019
   PubMed Web of Science ®Google Scholar
• M.K.ChoE.S.SunY.H.KimZinc-triggered induction of tissue plasminogen activator and plasminogen in endothelial cells and pericytesExp Neurobiol222013315321
   Google Scholar
• T.IwaiT.SawabeK.TanimitsuM.SuzukiS.Sasaki-HamadaJ.OkaGlucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodentsJ Neurosci Res922014446454
   PubMed Web of Science ®Google Scholar
• M.Q.XueX.X.LiuY.L.ZhangF.G.GaoNicotine exerts neuroprotective effects against beta-amyloid-induced neurotoxicity in SH-SY5Y cells through the Erk1/2-p38-JNK-dependent signaling pathwayInt J Mol Med332014925933
   PubMed Web of Science ®Google Scholar
• A.GhanemiB.BoubertakhShorter and sturdier bridges between traditional Chinese medicines and modern pharmacologySaudi Pharm J2014 http://dx.doi.org/10.1016/j.jsps.2014.02.010
   Web of Science ®Google Scholar
• H.BahraniJ.MohamadM.J.PaydarH.A.RothanIsolation and characterisation of acetylcholinesterase inhibitors from Aquilaria subintegra for the treatment of Alzheimer’s disease (AD)Curr Alzheimer Res201410.2174/1567205011666140130151344
   Web of Science ®Google Scholar
• Yaghmaei P, Azarfar K, Dezfulian M, Ebrahim-Habibi A. Silymarin effect on amyloid-beta plaque accumulation and gene expression of APP in an Alzheimer’s disease rat model. Daru: J Faculty Pharm, Tehran Univ Med Sci 2014;22:24.
   Google Scholar
• B.BoubertakhX.-G.LiuX.-L.ChengP.LiA spotlight on chemical constituents and pharmacological activities of Nigella glandulifera Freyn et Sint SeedsJ Chem2013201312
   Web of Science ®Google Scholar
• Ghanemi A. Animal models of Alzheimer’s disease: Limits and challenges. NPG Neurologie – Psychiatrie – Gériatrie 2014, http://dx.doi.org/10.1016/j.npg.2014.05.008.
   Google Scholar
• J.LaiM.HuH.WangMontelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Abeta1-42-induced memory impairment and neuroinflammatory and apoptotic responses in miceNeuropharmacology792014707714
   PubMed Web of Science ®Google Scholar
• T.A.CouttasN.KainB.DanielsLoss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesisActa Neuropathol Commun220149
   Web of Science ®Google Scholar
• A.A.PimenovaA.ThathiahB.De StrooperI.TesseurRegulation of amyloid precursor protein processing by serotonin signalingPLoS One92014e87014
   Web of Science ®Google Scholar
• J.ChewD.H.S.SilvermanFDG-PET in early AD diagnosisMed Clin North Am972013485494
   Web of Science ®Google Scholar
• E.Calvo-OchoaC.AriasCellular and metabolic alterations in the hippocampus caused by insulin signaling dysfunction and its association with cognitive impairment during aging and Alzheimer’s disease. Animal models of studyDiabetes Metab Res Rev201410.1002/dmrr.2531
   Web of Science ®Google Scholar
• E.KarranJ.HardyAntiamyloid therapy for Alzheimer’s disease–are we on the right road?N Engl J Med3702014377378
   PubMed Web of Science ®Google Scholar
• J.J.AriasJ.KarlawishConfidentiality in preclinical Alzheimer disease studies: when research and medical records meetNeurology822014725729
   Web of Science ®Google Scholar